15 percent revenue growth driven by improved utilization
Financial highlights Q2 2023
Net sales amounted to 21.1 MSEK (18.3), an increase of 15 percent over the same period in 2022
Operating result amounted to -4.7 MSEK (+0.1).
Net result after financial items amounted to -4.7 MSEK (-0.2).
Earnings per share were-0.07 SEK (0.00).
Cash Balance amounted to 5.4 MSEK (7.3).
Average Daily Treatment Revenue (ADTR)* was 241 TSEK (201), an increase of 20 percent over the same period in 2022.
Business highlights during the period
Dignitana announced a proposal for Local Coverage Determination of scalp cooling therapy for seven states in the Southeastern United States.
Dignitana exhibited at the Oncology Nursing Congress in San Antonio, Texas.
Dignitana co-sponsored a scalp cooling session at the Multinational Association of Supportive Care in Cancer conference in Japan along with exhibiting at the conference.
In May Dignitana published the Annual Report for 2022.
Dignitana's Annual General Meeting was held on 25 May 2023.
Business highlights after the period
Five year follow up results from the DigniCap pivotal trial were published in the Journal of Supportive Care in cancer demonstrating both safety and efficacy in the first long term study of scalp cooling.
Dignitana announced that the partnership with oneservice has expanded to now provide service in the field to DigniCap customers in Europe.
DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap's longtime partner there.
Key Figures
+-----------------------+-------+-------+----------+----------+--------------+
|DIGNITANA GROUP        |Q2 2023|Q2 2022|Q1-Q2 2023|Q1-Q2 2022|Full Year 2022|
+-----------------------+-------+-------+----------+----------+--------------+
|Net sales, TSEK        |21,089 |18,284 |42,578    |34,148    |72,995        |
+-----------------------+-------+-------+----------+----------+--------------+
|Total revenues, TSEK   |23,159 |24,067 |44,764    |40,777    |83,849        |
+-----------------------+-------+-------+----------+----------+--------------+
|Net profit after       |-4,662 |-232   | -8,600   |-6,740    |-22,396       |
|financial items, TSEK  |       |       |          |          |              |
+-----------------------+-------+-------+----------+----------+--------------+
|Cash and bank balances,|5,423  |7,312  |5,423     |7,312     |8,869         |
|TSEK                   |       |       |          |          |              |
+-----------------------+-------+-------+----------+----------+--------------+
|Earnings per share     |-0.07  |0.00   |-0.12     |-0.10     |-0.34         |
|before and after       |       |       |          |          |              |
|dilution, SEK          |       |       |          |          |              |
+-----------------------+-------+-------+----------+----------+--------------+
|Average Daily Treatment|241    |201    |242       |190       |203           |
|revenue*, TSEK         |       |       |          |          |              |
+-----------------------+-------+-------+----------+----------+--------------+
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"With a focus on device utilization, our circular business model creates, captures and delivers value by redeploying underutilized devices and thus maximizing revenue potential and fostering sustainable use of assets." - Catarina Löwenadler, CEO Dignitana AB
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-08-2023 08:09 CET.